文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

基于胱抑素C的给药诺模图改善重症患者头孢吡肟目标达成

Cystatin C-Guided Dosing Nomogram Improves Target Attainment for Cefepime in the Critically Ill.
PubMed 文献 · Crit Care Med · 2025-02-27
一句话结论基于eGFR cr-cys与体重的头孢吡肟初始给药诺模图,预测24小时100% ƒT>MIC达成率76%,高于实际给药38%(p<0.001)。

本研究为药代动力学建模与模拟研究,纳入120例接受头孢吡肟治疗的重症成人患者,利用基线胱抑素C和随访头孢吡肟浓度数据,构建基于联合肌酐与胱抑素C估算的肾小球滤过率(eGFR cr-cys)和体重的初始给药诺模图。结果显示,诺模图预测的24小时100% ƒT>MIC达成率显著优于实际给药剂量(76% vs. 38%,p<0.001);诺模图预测的中位ƒAUC0-24略高于实际给药(666 mg·hr/L vs. 612 mg·hr/L,p=0.01),但ƒAUC0-24过高(>900)或过低(<300)的比例更少(7% vs. 20%,p=0.004)。作者认为,使用包含胱抑素C的给药诺模图可改善重症患者头孢吡肟的目标达成,且不增加潜在毒性水平风险。

要点

  • 在120例重症成人中,基于eGFR cr-cys和体重的头孢吡肟诺模图预测24小时100% ƒT>MIC达成率为76%,实际给药为38%(p<0.001)。
  • 诺模图预测的中位ƒAUC0-24为666 mg·hr/L,实际给药为612 mg·hr/L(p=0.01)。
  • 诺模图使ƒAUC0-24过高(>900)或过低(<300)的比例从20%降至7%(p=0.004)。
  • 作者认为,包含胱抑素C的给药诺模图可改善重症患者头孢吡肟初始给药的目标达成,且不增加潜在毒性水平风险。

适用人群与场景

  • 接受头孢吡肟治疗的重症成人患者,来自学术医疗中心。

诊断标准与关键阈值

  • 采用基于eGFR cr-cys和体重的诺模图进行头孢吡肟初始给药。
  • 目标达成定义为首次24小时内100% ƒT>MIC。
  • ƒAUC0-24过高定义为>900 mg·hr/L,过低定义为<300 mg·hr/L。

研究设计与关键结果

  • 研究类型为药代动力学建模与模拟研究,纳入120例有基线胱抑素C和随访头孢吡肟浓度的重症成人患者。
  • 主要终点:诺模图预测的24小时100% ƒT>MIC达成率为76%,实际给药为38%(p<0.001)。
  • 次要终点:诺模图预测的中位ƒAUC0-24为666 mg·hr/L,实际给药为612 mg·hr/L(p=0.01)。
  • 诺模图组ƒAUC0-24过高(>900)或过低(<300)的比例为7%,实际给药组为20%(p=0.004)。

证据类型、等级与局限

  • 证据类型:药代动力学建模与模拟研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,使用包含胱抑素C的给药诺模图可改善重症患者头孢吡肟初始给药的目标达成,且不增加潜在毒性水平风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Estimated glomerular filtration rate is more accurate with combined creatinine and cystatin C equations (eGFR cr-cys ) than creatinine alone. This study created and evaluated a cefepime dosing nomogram based on eGFR cr-cys for initial dosing in the critically ill.

DESIGN: Pharmacokinetic modeling and simulation study.

SETTING: Academic medical center.

PATIENTS: Critically ill adults treated with cefepime.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Data from 120 patients with baseline cystatin C and follow-up cefepime levels were used to develop a nomogram based on eGFR cr-cys and weight for initial cefepime dosing. The predicted proportion of patients who achieved a free cefepime concentration above the minimum inhibitory concentration of the organism for 100% of the dosing interval in the first 24 hours (100% ƒT > MIC at 24 hr) was compared between administered doses and those predicted by the nomogram doses. Overall drug exposure was estimated with the free area under the concentration time curve from 0 to 24 hours (ƒAUC 0-24 ) and compared between administered and nomogram doses. Achievement of 100% ƒT > MIC at 24 hours was predicted to be significantly better with the nomogram compared with the administered dose (76% vs. 38%; p < 0.001). The median ƒAUC 0-24 as predicted by the nomogram (666 mg·hr/L) was slightly higher than the actual ƒAUC 0-24 with administered doses (612 mg·hr/L; p = 0.01), but the nomogram led to fewer ƒAUC 0-24 values which were either too high (> 900) or too low (< 300) (7% vs. 20%; p = 0.004).

CONCLUSIONS: Use of a cystatin C-inclusive dosing nomogram for cefepime could improve target attainment without increasing the risk of potentially toxic levels in the critically ill.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Barreto EF, Scheetz MH, Chang J, et al. Cystatin C-Guided Dosing Nomogram Improves Target Attainment for Cefepime in the Critically Ill. Crit Care Med. 2025. PMID: 40013864. doi:10.1097/CCM.0000000000006622

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。